FindTrial
Sign In

A medical records based study for Sorafenib combined with TACE sequential regorafenib combined with TACE versus sorafenib in combination with TACE sequential regofenib in the treatment of patients with advanced hepatocellular carcinoma

A medical records based study for Sorafenib combined with TACE sequential regorafenib combined with TACE versus sorafenib in combination with TACE sequential regofenib in the treatment of patients with advanced hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027692
Enrollment
Unknown
Registered
2019-11-23
Start date
2020-04-23
Completion date
Unknown
Last updated
2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Group A:Sorafenib combined with TACE sequential regorafenib combined with TACE
Group B:Sorafenib combined with TACE sequential regorafenib

Sponsors

Jiangsu Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years old; 2. Diagnosis of hepatocellular carcinoma; 3. BCLC Phase B or Phase C in accordance with TACE; 4. Child-Pugh grade A or B; 5. ECOG score 0-2.

Exclusion criteria

Exclusion criteria: 1. received systemic treatment; 2. A person who has been confirmed to be allergic to sorafenib or regorafenib and/or its excipients; 3. Pregnant or lactating women; 4. Sorafenib, regorafenib or patients with TACE contraindications; 5. Patients with bleeding tendency; 6. The investigator believes that it is not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Overall survival;—

Countries

China

Contacts

Public ContactGuowen Yin

Jiangsu Cancer Hospital

jsnjygw@163.com+86 025-83284755

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026